Jiajun Wen

Jiajun Wen

Auto-generated profile, based on publicly available information

Jiajun Wen

Department of Anesthesiology, Guangzhou University of Traditional Chinese Medicine ShunDe Traditional Chinese Medicine Hospital

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2026 in Annals of Medicine
Verified
Journal Article
Open access
HPHaobin Peng
Haobin Peng
JWJiajun Wen
Jiajun Wen
YJYing Jiang
Ying Jiang
JOJianxin Ou
Jianxin Ou
XWXianping Wu
Xianping Wu
MCManli Chen
Manli Chen
Transcutaneous auricular vagus nerve stimulation (taVNS) provides targeted modulation of the autonomic nervous system and descending pain pathways, exerting analgesic potential. However, high-quality evidence remains insufficient to determine whether taVNS can effectively replace opioids in sedation regimens for same-session bidirectional endoscopy while maintaining the quality of early postoperative recovery. This study is a single-center, prospective, randomized, double-blind, placebo-controlled, three-arm non-inferiority trial. A total of 181 patients scheduled for painless same-session bidirectional endoscopy will be enrolled and randomly assigned using dynamic block randomization to one of three groups: Group S (sufentanil 0.1 µg/kg plus sham taVNS), Group T (normal saline plus active taVNS), and Group P (normal saline plus sham taVNS). All participants will receive ciprofol for sedation induction and maintenance. The primary outcome will be the quality of recovery at 24 h postoperatively, assessed using the 15-item Quality of Recovery scale (QoR-15), with a predefined non-inferiority margin (δ) of 6 points, which corresponds to the minimal clinically important difference of the QoR-15 scale. Secondary outcomes will include perioperative adverse events (pre-, intra-, and postoperative, including taVNS-related events), QoR-15 score at 1 h postoperatively, procedural and recovery efficiency indices, sedative dosage, and patient and endoscopist satisfaction scores. Blinding effectiveness will be assessed in all participants, and statistical analyses will follow the modified intention-to-treat principle. This study protocol will rigorously assess the effectiveness and safety of taVNS as an alternative to opioid analgesics for sedation during same-session bidirectional endoscopy using, to our knowledge, the first three-arm design.Trial registration: Chinese Clinical Trial Registry (ChiCTR2600117962).

1 May 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
JWJiajun Wen
Jiajun Wen
HPHaobin Peng
Haobin Peng
YJYing Jiang
Ying Jiang
MCManli Chen
Manli Chen
JOJianxin Ou
Jianxin Ou
XWXianping Wu
Xianping Wu
The efficacy of the adductor canal block (ACB) in multimodal analgesia following total knee arthroplasty (TKA) remains controversial. This study investigates the effects of local anesthetics single-injection ACB with different analgesic durations on TKA patients. This randomized controlled double‑blinded trial enrolled 90 patients undergoing primary TKA. Participants were randomized to receive ACB with either liposomal bupivacaine (LB), ropivacaine (15 mL of 0.3%), or in the control group, with 30 patients in each group. The primary end points included the static and dynamic visual analog scale (VAS) scores at 24 hours postoperatively. The secondary end points examined the static and dynamic pain scores at 6,12,48, and 72 hours postoperatively; the knee range of motion (ROM); quadriceps muscle strength; duration to first ambulation; opioid consumption; and related adverse events. Patients administered a LB single-injection ACB (LB-ACB) demonstrated significantly reduced VAS scores at static and dynamic phases at 24 hours, relative to the ropivacaine single-injection ACB (R-ACB) and control group patients. We recorded a median interquartile range [IQR] of 1 (0.0–2.0 [0–4]) vs. 3 (2.0–4.0 [0–5]) vs. 3 (2.0–4.0 [0–6]) for static pain scores and 2.5 (1.0–3.25 [0–5]) vs. 4 (4.0–5.0 [2–7]) vs. 5 (4.0–6.0 [3–7]) for dynamic pain scores (P<0.001). Both LB-ACB and R-ACB groups showed lower pain scores at 6 and 12 hours postoperatively versus control (P<0.05). Time to first rescue analgesia was prolonged in the LB group, and LB-ACB also improved early quadriceps strength and knee ROM. No significant adverse events or motor blockade occurred. Among patients undergoing TKA, LB single-injection ACB offers a significant analgesic advantage compared to ropivacaine, lasting up to 24 hours. After 48 hours, there is no difference in analgesic effects when compared to the control group.